** Shares of drugmaker Amgen AMGN.O fall 5.8% to $272.64
** Company says people started on a low dose of its experimental obesity drug, MariTide, achieved weight loss comparable to those on higher doses, while experiencing milder side effects in a mid-stage clinical trial
** Company adds that vomiting was reported in nearly 90% of patients started at the highest tested dose, compared with 50% of patients who ramped up to a full dose in one step and 22% of those brought to their target dose over eight weeks
** In late-stage trials, Novo Nordisk's NOVOb.CO GLP-1 obesity drug Wegovy had a vomiting rate of 24%, while Eli Lilly's LLY.N Zepbound had a rate of 13%
** Amgen says trial discontinuation rates due to gastrointestinal issues of up to 7.8% were lower for groups treated with escalating doses
** Amgen plans to initiate additional late-stage studies this year to test MariTide in patients with various serious health conditions
** Including session moves, stock up 5.2% YTD
(Reporting by Sneha S K)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。